Aakaar Medical Technologies Limited — PPTs, 10-11-2025: Investor Presentation

Aakaar Medical Technologies reported H1FY26 results with revenue at ₹25.3 Cr, an 8.6% YoY drop. Operating EBITDA significantly declined to ₹0.07 Cr, and the company posted a net loss of ₹0.8 Cr. Management attributed this to typical H1 seasonality, a strategic tightening of credit terms, and one-time expenses for conferences. Inventory was temporarily higher due to regulatory shifts and packaging changes.

Looking ahead, Aakaar is focusing on strengthening cash flow through stricter billing and expanding its customer base. The company launched EXOVEA, a new high-margin division expected to add ₹6 Cr in its first year. IPO funds of ₹27 Cr will bolster working capital, with plans to reduce receivable days significantly. Management anticipates a healthy rebound in H2, driven by improved demand and efficient operations, expecting growth from its owned brands and wider distribution.